By Counterforce Health Team in Strimvelis (autologous CD34+ ADA-SCID gene therapy) —

Getting Strimvelis Gene Therapy Covered by UnitedHealthcare in North Carolina: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Strimvelis Covered by UnitedHealthcare in North Carolina

UnitedHealthcare requires prior authorization for Strimvelis (autologous CD34+ ADA-SCID gene therapy) as a non-formulary, international specialty treatment. Start by confirming your ADA-SCID diagnosis with genetic testing, documenting failed or contraindicated alternatives, and submitting through the UHC Provider Portal. If denied, use UnitedHealthcare's internal appeals, then North Carolina's Smart NC external review (for fully insured plans), which overturns about 40-50% of medical necessity denials. First step today: Call UnitedHealthcare member services to confirm your plan type and prior authorization requirements.

Table of Contents

  1. Coverage at a Glance
  2. Fastest Path to Approval
  3. Prior Authorization Requirements
  4. Medical Necessity Documentation
  5. Common Denial Reasons & Solutions
  6. Appeals Process: Internal and External
  7. North Carolina Smart NC External Review
  8. Treatment Timeline and Bridge Therapy
  9. Cost Support and Financial Assistance
  10. FAQ

Coverage at a Glance

Requirement What It Means Where to Find It Source
Prior Authorization Mandatory for all gene therapies UHC Provider Portal UHC PA Requirements
Formulary Status Non-formulary, case-by-case review Member portal or ID card OptumRx Formulary
Site of Care SR-TIGET Milan only EMA authorization EMA Strimvelis
Diagnosis Required Confirmed ADA-SCID with genetic testing FDA labeling equivalent NICE HST7
Appeals Deadline 180 days from denial (internal) Plan documents Standard UHC policy
External Review 120 days after final internal denial Smart NC program NC DOI Smart NC

Fastest Path to Approval

1. Verify Plan Eligibility (Patient/Family)

  • Call UnitedHealthcare member services (number on ID card)
  • Ask: "Is my plan fully insured in North Carolina or self-funded?"
  • Confirm: Prior authorization requirements for international gene therapy
  • Timeline: Same day

2. Gather Essential Documentation (Treating Physician)

  • ADA-SCID diagnosis: Genetic testing results showing pathogenic ADA variants
  • Enzyme levels: Confirmed ADA deficiency in blood/tissues
  • Treatment history: Documentation of PEG-ADA use and outcomes
  • Timeline: 1-2 weeks to compile

3. Submit Prior Authorization (Provider)

  • Use: UHC Provider Portal
  • Include: Complete medical necessity letter and supporting documentation
  • Timeline: Submit 30-45 days before planned treatment

4. Prepare for Milan Coordination (All)

  • Contact: SR-TIGET for treatment scheduling
  • Coordinate: Travel arrangements and international coverage
  • Timeline: 2-3 months lead time typical
Tip: Start the prior authorization process immediately after ADA-SCID diagnosis, even while arranging Milan consultation. Early approval prevents treatment delays.

Prior Authorization Requirements

UnitedHealthcare treats Strimvelis as a high-touch specialty service requiring comprehensive clinical review. Based on UnitedHealthcare's general approach to gene therapies and orphan drugs, expect these requirements:

Essential Clinical Criteria

  • Confirmed ADA-SCID diagnosis with genetic testing
  • ADA enzyme deficiency documented in laboratory studies
  • Age and weight parameters meeting treatment protocol
  • Absence of suitable HLA-matched related donor for HSCT
  • Medical stability for international travel and procedure

Documentation Requirements

  • Genetic testing report showing pathogenic ADA gene variants
  • Immunological assessment including lymphocyte subsets and function
  • Treatment history with PEG-ADA enzyme replacement therapy
  • Specialist consultation from pediatric immunologist or similar expert
  • Treatment plan from SR-TIGET Milan with cost estimates

Counterforce Health helps patients and clinicians navigate complex prior authorization requirements by analyzing denial patterns and building evidence-backed appeals that align with payer-specific criteria.

Medical Necessity Documentation

Clinician Corner: Medical Necessity Letter Checklist

Your medical necessity letter should address these key points:

Clinical Problem

  • Severity of ADA-SCID and life-threatening nature
  • Specific manifestations (recurrent infections, failure to thrive)
  • Laboratory confirmation of diagnosis

Prior Treatments and Outcomes

  • PEG-ADA enzyme replacement therapy duration and response
  • Supportive care measures (IVIG, prophylactic antibiotics)
  • Limitations of current bridging therapy

Clinical Rationale for Strimvelis

  • EU regulatory approval for ADA-SCID (EMA authorization)
  • Published efficacy data showing immune reconstitution
  • Long-term outcomes from clinical trials and registry data
  • Lack of curative alternatives when no matched donor available

Treatment Plan

  • Pre-treatment evaluation and conditioning protocol
  • Post-treatment monitoring and follow-up requirements
  • Expected outcomes and success metrics
Note: Include specific citations from peer-reviewed literature and regulatory documents. The NICE HST7 guidance provides comprehensive clinical evidence review.

Common Denial Reasons & Solutions

Denial Reason How to Overturn Key Documents
"Not medically necessary" Cite EMA approval and published efficacy data FDA-equivalent labeling, NICE HST7
"Experimental/investigational" Document EU regulatory approval since 2016 EMA marketing authorization
"No suitable alternatives tried" Show PEG-ADA bridge therapy limitations Treatment history, enzyme levels
"Out-of-network coverage" Request single-case agreement for Milan center SR-TIGET treatment plan
"Insufficient documentation" Provide comprehensive genetic and immunologic workup Lab reports, specialist letters

Appeals Process: Internal and External

UnitedHealthcare Internal Appeals

Level 1: Standard Internal Appeal

  • Timeline: Submit within 180 days of denial
  • Review period: Up to 30 days for standard review
  • Expedited option: 72 hours for urgent cases
  • Submission: UHC Provider Portal or written appeal

Level 2: Second Internal Appeal (if applicable)

  • Timeline: 60 days after Level 1 denial
  • Review period: 30 days
  • Include: Additional clinical evidence, peer-reviewed studies

Required Appeal Documentation

  • Original denial letter with specific reasons
  • Updated medical necessity letter addressing denial points
  • Additional clinical evidence not in original submission
  • Expert opinion letters from ADA-SCID specialists
Tip: Request an expedited review if treatment delays could seriously jeopardize health. ADA-SCID's life-threatening nature typically qualifies for expedited processing.

North Carolina Smart NC External Review

For fully insured UnitedHealthcare plans in North Carolina, you have access to the state's external review program after exhausting internal appeals.

Smart NC Eligibility

  • Plan type: Fully insured plans regulated by North Carolina
  • Denial basis: Medical necessity or experimental/investigational determination
  • Timing: Within 120 days of final internal denial
  • Success rate: Approximately 40-50% of medical necessity denials overturned

Filing External Review

  1. Contact Smart NC: Call 1-855-408-1212 for guidance
  2. Complete forms: External review request form from NC DOI website
  3. Submit documentation:
    • All UnitedHealthcare denial and appeal letters
    • Complete medical record supporting Strimvelis need
    • Treating specialist letter
    • Clinical guidelines and evidence

Expedited External Review

Available when delay would seriously jeopardize life or health function:

  • Decision timeline: Within 72 hours of acceptance
  • May waive: Internal appeal completion requirement
  • Particularly relevant: For ADA-SCID given life-threatening nature

The external review decision is binding on UnitedHealthcare - if overturned, coverage must be provided within 3 business days.

Treatment Timeline and Bridge Therapy

Managing PEG-ADA During Strimvelis Planning

Strimvelis is a one-time curative gene therapy, but patients typically require continuous PEG-ADA enzyme replacement therapy as a bridge until treatment:

Pre-Strimvelis Phase

  • Continue PEG-ADA throughout approval and travel planning
  • Monitor immune function with regular lab work
  • Coordinate timing to minimize bridge therapy duration

Treatment Phase

  • Stop PEG-ADA before conditioning (per protocol)
  • Milan hospitalization for bone marrow harvest and gene therapy
  • Post-infusion monitoring at SR-TIGET (60-90 days typical)

Post-Treatment Follow-up

  • Home country monitoring starting around 3-4 months
  • Long-term registry participation required
  • PEG-ADA restart only if gene therapy fails
Important: Never allow unplanned interruption of PEG-ADA before successful Strimvelis engraftment. Coverage gaps can be life-threatening.

Cost Support and Financial Assistance

Manufacturer and Foundation Programs

  • Orchard Therapeutics patient support programs (verify current availability)
  • Rare disease foundations offering travel and treatment grants
  • State programs for rare disease treatment access

UnitedHealthcare Cost Management

  • Single-case agreements for out-of-network Milan treatment
  • Travel benefit coordination if included in plan
  • Case management services for complex care coordination

Counterforce Health's platform can help identify cost-offset arguments and financial assistance options while building your coverage appeal.

FAQ

How long does UnitedHealthcare prior authorization take for Strimvelis? Standard review takes up to 30 days, but complex gene therapy cases may require additional time. Request expedited review (72 hours) if medically urgent.

What if Strimvelis is not on UnitedHealthcare's formulary? Strimvelis is typically non-formulary and requires medical exception review. This is standard for EU-approved therapies not yet available in the US.

Can I appeal if I have a self-funded employer plan? Self-funded ERISA plans cannot use North Carolina's Smart NC external review. Use the plan's internal appeals process and any federal external review options.

Does step therapy apply to Strimvelis? Step therapy typically requires trying PEG-ADA enzyme replacement first, which is standard medical practice for ADA-SCID bridging.

How do I prove medical necessity for international treatment? Document that SR-TIGET Milan is the only authorized treatment center globally, supported by EMA regulatory approval and published protocols.

What happens if my appeal is denied? For fully insured plans, use Smart NC external review. Consider legal consultation for complex cases or if procedural errors occurred.

Can treatment be delayed while appealing? Continue PEG-ADA bridge therapy throughout the appeals process. Never stop supportive treatment while awaiting coverage decisions.

What if I move to another state during treatment? Coordinate with UnitedHealthcare case management to ensure coverage continuity across state lines and international treatment phases.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical advice. Coverage decisions depend on individual plan terms and clinical circumstances. Always consult with your healthcare provider and insurance company for specific guidance. For additional support with complex prior authorizations and appeals, consider consulting with healthcare coverage specialists.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.